Home › Compare › FISOF vs ABBV
FISOF yields 852.88% · ABBV yields 3.06%● Live data
📍 FISOF pulled ahead of the other in Year 1
Combined, FISOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FISOF + ABBV for your $10,000?
Fission 3.0 Corp. engages in the acquisition, exploration, and development of uranium resource properties. The company holds 100% interests in the Clearwater West property that comprises 3 contiguous claims covering 11,786 hectares located in Saskatchewan, Canada; the Patterson Lake North property that consists of 38 claims covering 39,946 hectares situated in Saskatchewan, Canada; the Wales Lake property that comprises 31 claims covering an area of 40,986 hectares located in southwest Athabasca basin; and the Key Lake area portfolio consisting of the Bird Lake, Grey Island, Hobo Lake, Lazy Edward Bay, and Seahorse Lake properties, which comprise 81 claims and 57,131 hectares located in Saskatchewan, Canada. It also has 100% interests in the Beaverlodge/uranium city area portfolio that consists of 50 claims and 41,537 hectares located in Saskatchewan, Canada; and the northeast Athabasca basin area, which comprise 36 claims covering an area of 21,059 hectares situated in Saskatchewan, Canada. The company was incorporated in 2013 and is headquartered in Kelowna, Canada.
Full FISOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.